Vascular endothelial growth factor in lacrimal fluid as a marker of the effectiveness of treatment of patients with diabetic retinopathy against the background of hypertension

Abstract

Сentral role in the development of diabetic retinopathy. The biological effect
is mediated by binding to specific receptors on the cell surface . Ranibizumab (lucentis)
is an antigen-binding fragment of a humanized monoclonal antibody to endothelial
growth factor A (VEGF-A). Ranibizumab prevents the interaction of all VEGF-A
isoforms with its VEGFR1 and VEGR2 receptors on the surface of endothelial cells,
which leads to suppression of vascular proliferation and neovascularization .